On October 12, Almazov Centre hosted the All-Russian Conference on Technologies of Nitric Oxide Use in Medicine: Current State and Prospects.
For the first time, a single thematic scientific forum brought together representatives of several scientific institutions conducting technical, experimental biological and clinical research in the field of medical applications of nitric oxide (NO).
The necessity for this meeting arises from Russia's emergence as a global frontrunner in the development of NO-based medical technologies over the past five years.
The research carried out at the All-Russian Research Institute of Experimental Physics of the Federal Nuclear Centre under the guidance of Prof. V.D. Selemir, Corresponding Member of the Russian Academy of Sciences, has yielded significant results. A groundbreaking technology for NO generation from atmospheric air by pulsed electrical discharge was developed. The Tianox device based on this technology was authorized for medical use in 2020 and expanded the use of inhaled NO therapy due to reduced costs and simplified clinical use.
Today, Russia is the only country in the world with an authorized technology for generating NO from atmospheric air. This innovative technology has become the basis for an active scientific search for new clinical applications of NO. The current discussion encompasses not only traditional indications for prescribing NO as an effective and selective small-circle vasodilator, but also the recently discovered cerebroprotective, cardioprotective, antibacterial and antiviral properties of this gas.
The data on experimental biological and clinical studies of these properties of NO were presented at the conference. The forum illustrated a significant contemporary trend: the use of nitric oxide is no longer confined to cardiology and intensive care, but has instead become a multifaceted medical technology.